A Randomized, Phase 2 Study of Oral BGE-102 in Participants With Center-Involved Diabetic Macular Edema
Public ClinicalTrials.gov record NCT07812090. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Masked, Multicenter Phase 2 Study Evaluating the Efficacy, Safety, and Tolerability of Oral BGE-102 as Mono- and Combination Therapy in Participants With Center-Involved Diabetic Macular Edema
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to learn about the effects of BGE-102 on change in vision in participants with center-involved diabetic macular edema (CI-DME). BGE-102 decreases inflammation which may improve vision or slow the progression of vison loss in those with CI-DME. Participants will be randomized to one of 3 arms and receive either BGE-102 in combination with an anti-vascular endothelial growth factor (anti-VEGF) drug, BGE-102 in combination with sham injection, or BGE-102 placebo in combination with an anti-VEGF drug. This study will also evaluate safety and tolerability of BGE-102.
Study identification
- NCT ID
- NCT07812090
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 180 participants
Conditions and interventions
Conditions
Interventions
- Oral BGE-102 Drug
- Oral Placebo Matching BGE-102 Drug
- Anti-VEGF Drug
- Sham Other
Drug · Other
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 21, 2026 (Actual)
- Primary completion
- Nov 2027 (Estimated)
- Completion
- Dec 2027 (Estimated)
- Last update posted
- Oct 27, 2026
2026 – 2027
United States locations
- U.S. sites
- 16
- U.S. states
- 6
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site 104 | Bakersfield | California | 93309 | Recruiting |
| Site 105 | Glendale | California | 91204 | Recruiting |
| Site 118 | Mountain View | California | 94040 | Recruiting |
| Site 128 | Fort Myers | Florida | 33912 | Recruiting |
| Site 113 | South Miami | Florida | 33143 | Recruiting |
| Site 119 | West Monroe | Louisiana | 71291 | Recruiting |
| Site 117 | Cary | North Carolina | 27511 | Recruiting |
| Site 116 | Wake Forest | North Carolina | 27587 | Recruiting |
| Site 101 | Ladson | South Carolina | 29456 | Recruiting |
| Site 111 | Abilene | Texas | 79606 | Recruiting |
| Site 129 | Austin | Texas | 78750 | Recruiting |
| Site 130 | Houston | Texas | 77030 | Recruiting |
| Site 125 | Laredo | Texas | 78041 | Recruiting |
| Site 106 | McAllen | Texas | 78503 | Recruiting |
| Site 110 | San Antonio | Texas | 78240 | Recruiting |
| Site 108 | The Woodlands | Texas | 77384 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07812090, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 27, 2026 · Synced Oct 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT07812090 live on ClinicalTrials.gov.